Does the media favor ASND or TNGX?

In the previous week, Ascendis Pharma A/S had 3 more articles in the media than Tango Therapeutics. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 4 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.57 beat Ascendis Pharma A/S's score of 1.01 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor BBIO or TNGX?

In the previous week, BridgeBio Pharma had 14 more articles in the media than Tango Therapeutics. MarketBeat recorded 18 mentions for BridgeBio Pharma and 4 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.57 beat BridgeBio Pharma's score of 0.70 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer TNGX or AXSM?

In the previous week, Axsome Therapeutics had 8 more articles in the media than Tango Therapeutics. MarketBeat recorded 12 mentions for Axsome Therapeutics and 4 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.57 beat Axsome Therapeutics' score of 0.75 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Axsome Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELAN or TNGX?

In the previous week, Tango Therapeutics had 1 more articles in the media than Elanco Animal Health. MarketBeat recorded 4 mentions for Tango Therapeutics and 3 mentions for Elanco Animal Health. Tango Therapeutics' average media sentiment score of 1.57 beat Elanco Animal Health's score of 1.16 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is TNGX or SMMT more profitable?

Tango Therapeutics' return on equity of -41.54% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tango Therapeutics N/A -41.54% -33.44% Summit Therapeutics N/A -291.24% -243.07%

Does the media prefer TNGX or SMMT?

In the previous week, Tango Therapeutics had 1 more articles in the media than Summit Therapeutics. MarketBeat recorded 4 mentions for Tango Therapeutics and 3 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.67 beat Tango Therapeutics' score of 1.57 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Summit Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Tango Therapeutics (TNGX) Competitors

$28.36 -2.70 (-8.69%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$28.68 +0.32 (+1.11%)

As of 07/13/2026 07:49 PM Eastern

Compare

TNGX vs. ASND, BBIO, AXSM, ELAN, and SMMT

Should you buy Tango Therapeutics stock or one of its competitors? MarketBeat compares Tango Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tango Therapeutics include Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Elanco Animal Health (ELAN), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.

How does Tango Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

79.0% of Tango Therapeutics shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Ascendis Pharma A/S has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

In the previous week, Ascendis Pharma A/S had 3 more articles in the media than Tango Therapeutics. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 4 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.57 beat Ascendis Pharma A/S's score of 1.01 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Ascendis Pharma A/S currently has a consensus target price of $295.67, indicating a potential upside of 11.48%. Tango Therapeutics has a consensus target price of $41.50, indicating a potential upside of 46.33%. Given Tango Therapeutics' higher possible upside, analysts clearly believe Tango Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

Tango Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Tango Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	20.31	-$258M	$8.67	30.59
Tango Therapeutics	$62.38M	65.76	-$101.59M	-$0.83	N/A

Ascendis Pharma A/S has a net margin of 57.87% compared to Tango Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Tango Therapeutics	N/A	-41.54%	-33.44%

Summary

Ascendis Pharma A/S beats Tango Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Tango Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

In the previous week, BridgeBio Pharma had 14 more articles in the media than Tango Therapeutics. MarketBeat recorded 18 mentions for BridgeBio Pharma and 4 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.57 beat BridgeBio Pharma's score of 0.70 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

BridgeBio Pharma has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tango Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Tango Therapeutics	N/A	-41.54%	-33.44%

Tango Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Tango Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	32.41	-$724.93M	-$3.74	N/A
Tango Therapeutics	$62.38M	65.76	-$101.59M	-$0.83	N/A

BridgeBio Pharma presently has a consensus price target of $94.63, indicating a potential upside of 13.90%. Tango Therapeutics has a consensus price target of $41.50, indicating a potential upside of 46.33%. Given Tango Therapeutics' higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

BridgeBio Pharma and Tango Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Tango Therapeutics compare to Axsome Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

Tango Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Tango Therapeutics' return on equity of -41.54% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-41.54%	-33.44%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Tango Therapeutics presently has a consensus price target of $41.50, indicating a potential upside of 46.33%. Axsome Therapeutics has a consensus price target of $259.05, indicating a potential upside of 13.48%. Given Tango Therapeutics' higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Tango Therapeutics has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

Tango Therapeutics has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	65.76	-$101.59M	-$0.83	N/A
Axsome Therapeutics	$638.50M	18.40	-$183.17M	-$3.73	N/A

In the previous week, Axsome Therapeutics had 8 more articles in the media than Tango Therapeutics. MarketBeat recorded 12 mentions for Axsome Therapeutics and 4 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.57 beat Axsome Therapeutics' score of 0.75 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Axsome Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tango Therapeutics beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Tango Therapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Elanco Animal Health has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

In the previous week, Tango Therapeutics had 1 more articles in the media than Elanco Animal Health. MarketBeat recorded 4 mentions for Tango Therapeutics and 3 mentions for Elanco Animal Health. Tango Therapeutics' average media sentiment score of 1.57 beat Elanco Animal Health's score of 1.16 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Tango Therapeutics has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.66	-$232M	-$0.50	N/A
Tango Therapeutics	$62.38M	65.76	-$101.59M	-$0.83	N/A

Tango Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Tango Therapeutics	N/A	-41.54%	-33.44%

Elanco Animal Health currently has a consensus price target of $28.55, indicating a potential upside of 13.61%. Tango Therapeutics has a consensus price target of $41.50, indicating a potential upside of 46.33%. Given Tango Therapeutics' higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Tango Therapeutics beats Elanco Animal Health on 9 of the 17 factors compared between the two stocks.

How does Tango Therapeutics compare to Summit Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Tango Therapeutics presently has a consensus price target of $41.50, indicating a potential upside of 46.33%. Summit Therapeutics has a consensus price target of $26.97, indicating a potential upside of 76.29%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

Tango Therapeutics has higher revenue and earnings than Summit Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	65.76	-$101.59M	-$0.83	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

In the previous week, Tango Therapeutics had 1 more articles in the media than Summit Therapeutics. MarketBeat recorded 4 mentions for Tango Therapeutics and 3 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.67 beat Tango Therapeutics' score of 1.57 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Summit Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Tango Therapeutics' return on equity of -41.54% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-41.54%	-33.44%
Summit Therapeutics	N/A	-291.24%	-243.07%

Tango Therapeutics has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.26, indicating that its stock price is 226% less volatile than the broader market.

Summary

Tango Therapeutics beats Summit Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Tango Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNGX vs. The Competition

Export

Metric	Tango Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.49B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-34.17	20.85	27.11	24.26
Price / Sales	65.76	314.01	587.92	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	11.04	8.49	10.75	6.29
Net Income	-$101.59M	$23.83M	$3.58B	$330.66M
7 Day Performance	-5.84%	-3.56%	-2.06%	-1.32%
1 Month Performance	-8.34%	6.31%	3.32%	-0.64%
1 Year Performance	365.68%	48.30%	26.35%	19.08%

Tango Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNGX Tango Therapeutics	2.9573 of 5 stars	$28.36 -8.7%	$41.50 +46.3%	+378.2%	$4.49B	$62.38M	N/A	90	News Coverage
ASND Ascendis Pharma A/S	4.3684 of 5 stars	$269.95 +0.8%	$295.67 +9.5%	+51.6%	$16.84B	$814.57M	31.14	1,189
BBIO BridgeBio Pharma	2.9882 of 5 stars	$78.46 +0.9%	$92.90 +18.4%	+78.8%	$15.38B	$502.08M	N/A	400	Analyst Forecast Insider Trade
AXSM Axsome Therapeutics	3.5179 of 5 stars	$250.57 +3.3%	$259.05 +3.4%	+109.5%	$12.90B	$638.50M	N/A	380
ELAN Elanco Animal Health	3.9026 of 5 stars	$24.79 -1.4%	$28.55 +15.2%	+68.7%	$12.40B	$4.72B	N/A	9,400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNGX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tango Therapeutics (TNGX) Competitors

TNGX vs. ASND, BBIO, AXSM, ELAN, and SMMT

How does Tango Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Tango Therapeutics compare to BridgeBio Pharma?

Summary

How does Tango Therapeutics compare to Axsome Therapeutics?

Summary

How does Tango Therapeutics compare to Elanco Animal Health?

Summary

How does Tango Therapeutics compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX vs. The Competition

Tango Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tango Therapeutics (TNGX) Competitors

TNGX vs. ASND, BBIO, AXSM, ELAN, and SMMT

How does Tango Therapeutics compare to Ascendis Pharma A/S?

Do insiders and institutionals have more ownership in ASND or TNGX?

Which has more risk & volatility, ASND or TNGX?

Does the media favor ASND or TNGX?

Do analysts rate ASND or TNGX?

Which has higher valuation and earnings, ASND or TNGX?

Is ASND or TNGX more profitable?

Summary

How does Tango Therapeutics compare to BridgeBio Pharma?

Does the media favor BBIO or TNGX?

Which has more risk and volatility, BBIO or TNGX?

Do insiders & institutionals have more ownership in BBIO or TNGX?

Is BBIO or TNGX more profitable?

Which has preferable earnings & valuation, BBIO or TNGX?

Do analysts rate BBIO or TNGX?

Summary

How does Tango Therapeutics compare to Axsome Therapeutics?

Is TNGX or AXSM more profitable?

Do analysts recommend TNGX or AXSM?

Do insiders and institutionals believe in TNGX or AXSM?

Which has more volatility and risk, TNGX or AXSM?

Which has higher valuation & earnings, TNGX or AXSM?

Does the media prefer TNGX or AXSM?

Summary

How does Tango Therapeutics compare to Elanco Animal Health?

Do institutionals and insiders have more ownership in ELAN or TNGX?

Which has more risk & volatility, ELAN or TNGX?

Does the media favor ELAN or TNGX?

Which has better valuation & earnings, ELAN or TNGX?

Is ELAN or TNGX more profitable?

Do analysts prefer ELAN or TNGX?

Summary

How does Tango Therapeutics compare to Summit Therapeutics?

Do insiders & institutionals believe in TNGX or SMMT?

Do analysts rate TNGX or SMMT?

Which has higher valuation and earnings, TNGX or SMMT?

Does the media prefer TNGX or SMMT?

Is TNGX or SMMT more profitable?

Which has more volatility and risk, TNGX or SMMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX vs. The Competition

Tango Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools